Fundraising Fox
ImmunoGenesis
Doylestown, US · Founded 2019 · Delaware corporation · 15 employees on LinkedIn · 7 known investors
Find your way into ImmunoGenesis
Sign up to see every warm intro you have to ImmunoGenesis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ImmunoGenesis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.
Founders & leadership
ImmunoGenesis was founded in 2019 by Michael A. Curran.
Board
Investors · 7
How we know: Adit Ventures Management, Llc's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Angel Physicians Fund's portfolio page · Not right? Tell us
How we know: BioAdvance's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Cancer Focus's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$50.2M disclosed across 2 rounds · 2024
▶$5.7MraisedJan 2025 · 2 investors · BiotechnologyRule 506(b)
- Michael A. CurranDirector
- Ted KoutouzisDirector
- Jennifer BarlowExecutive Officer, Director
- Robert B. SteinDirector
- Clifford StocksDirector
- Thomas BartonDirector
- Offering amount
- $25M
- Amount sold
- $5.7M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.4MraisedApr 2024 · 88 investors · BiotechnologyRule 506(b)
- James BarlowExecutive Officer, Director
- Michael CurranDirector
- Jeremy BartonExecutive Officer
- Thomas BartonDirector
- Robert SteinDirector
- Ted KoutouzisDirector
- Federica O'BrienExecutive Officer
- Federica PericleExecutive Officer
- Clifford StocksDirector
- Offering amount
- $66.5M
- Amount sold
- $44.4M
- Finders' fees
- $243K
- Placement agents
- Spartan Capital Securities, LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as ImmunoGenesis.
Frequently asked questions
- What does ImmunoGenesis do?
- ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.
- Who founded ImmunoGenesis?
- ImmunoGenesis was founded by Michael A. Curran in 2019.
- Who are ImmunoGenesis's investors?
- ImmunoGenesis's investors include 3Spoke Capital, Adit Ventures Management, Llc, Angel Physicians Fund, BioAdvance, Cancer Focus, Service Provider Capital, Texas HALO Fund.
- How much funding has ImmunoGenesis raised?
- ImmunoGenesis has disclosed $50.2M raised across 2 rounds.
- Where is ImmunoGenesis headquartered?
- ImmunoGenesis is headquartered in Doylestown, US.